268,000.00
-2,000.00
(-0.74%)
May 24 - Close
TYO
data delayed by 20 mins -
Disclaimer
Currency in JPY
| Range | 250,000.00 - 285,000.00 |
| 52 week | 26,300.00 - 375,000.00 |
| Open | 275,000.00 |
| Vol / Avg. | 6,537.00/8,947.00 |
| Mkt cap | 39.94B |
| P/E | - |
| Div/yield | - |
| EPS | -12,514.43 |
| Shares | 149,033.00 |
| Beta | - |
| Inst. own | - |
Events
Jul 29, 2013
Q2 2013 ANGES MG INC Earnings Release
Apr 26, 2013
Q1 2013 ANGES MG INC Earnings Release
Mar 28, 2013
ANGES MG INC Annual Shareholder Meeting (Japanese)
|
|
Key stats and ratios
| Q1 (Mar '13) | 2012 | |
| Net profit margin | -290.99% | -384.33% |
| Operating margin | -289.26% | -398.22% |
| EBITD margin | - | -380.63% |
| Return on average assets | -50.14% | -55.56% |
| Return on average equity | -60.54% | -68.20% |
| Employees | 58 | - |
| Carbon Disclosure Rating | - | - |
Address
7-7-15 Saito-asagi Saito Bio-Incubator 4 Fl.
IBARAKI-SHI, OSK 567-0085
Japan
+81-72-6433590 (Phone)
IBARAKI-SHI, OSK 567-0085
Japan
+81-72-6433590 (Phone)
Website links
External links
Discussion Group - Google Finance
Advertisement
Description
AnGes MG, Inc. is mainly engaged in the development of genetic medicines. The Company is segment the development of hepatocyte growth factor (HGF) genetic medicines, NF-KB decoy oligo, hemagglutinating virus of Japan envelope (HVJ-E) non-viral vector, among others. As of December 31, 2011, the Company had four consolidated subsidiaries. On September 1, 2011, the Company established a wholly owned subsidiary engaged in manufacturing and sales of healthcare products. On January 31, 2013, the Company sold a 95.3% stake of a Osaka-based subsidiary to ISHIHARA SANGYO KAISHA LTD.
Officers and directors
| Ei Yamada | President, Executive President, CEO of Subsidiary, Representative Director | |
| Shunsuke Sami | Vice President, Executive Officer, CEO of Subsidiary, Director | |
| Takahiro Nakasawa | Executive Officer, Chief Director of Research and Development | |
| Makoto Seki | Executive Officer, Chief Director of Business Planning | |
| Sadayoshi Yamanami | Executive Officer, Chief Director of Credibility Assurance | |
| Ichiro Kitazato | Independent Director | |
| Junichi Komamura | Independent Director |